Skip to content

Author

S. Suprianto

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Jul 2026

Governance And Performance-Based Reforms in School Education Under New Public Management: A Systematic Literature Review

The lack of an integrative framework in the literature hinders a comprehensive understanding of the relationship between New Public Management (NPM), governance, and performance-based reforms in education. This study aims to integrate this relationship through  a systematic literature review approach  based on the PRISMA protocol. Data was obtained from the Scopus database and selected using Rayyan through the stages of identification, screening, eligibility, and inclusion, resulting in 23 relevant articles. To ensure reliability and validity, the selection process is carried out systematically based on clear inclusion-exclusion criteria, filtering consistency, and analysis triangulation through bibliometric approaches and conceptual synthesis. The analysis was carried out using co-occurrence keyword analysis with VOSviewer and thematic mapping through Biblioshiny. The results of the study show that governance and performance-based reforms are one system that is integrated within the NPM framework. NPM acts as a central node that connects principles, governance mechanisms, policy instruments, and reform outcomes in interdependent relationships. Education reform takes place dynamically through a continuous cycle between policy formulation, implementation, evaluation, and feedback, with a performance-based control system as a liaison mechanism. This study produced an integrative model, namely the New Public Management–Based Systemic Integrative Governance and Education Reform (NPM-SIGER) Model, which represents education reform as a cyclical and adaptive system. These findings reposition NPM as an integrative governance paradigm, although the resulting model still requires further empirical testing.

S. Suprianto, Siti Rahmi, Ridwan Ridwan et al. · 0 citations
Open access Aug 2026

Gene therapy for rare diseases marks a new era in precision medicine: Insights from clinical trials

Gene therapy represents an important advance in the treatment of rare diseases, offering precise and transformative therapeutic strategies. As many rare diseases are associated with well-defined genetic variants, they represent ideal candidates for targeted genetic interventions. The substantial unmet medical need associated with rare diseases has driven growing interest in gene therapy, with more than 300 clinical trials reported to date. The aim of this study was to evaluate the current evidence on gene therapy for rare diseases by examining therapeutic strategies, target diseases, clinical progress, clinical outcomes, and emerging research trends. Several approved therapies, including those for hemophilia B, spinal muscular atrophy, metachromatic leukodystrophy, and Wiskott–Aldrich syndrome, have demonstrated the clinical potential of gene therapy. Clinical evidence suggests that gene-based therapies in the management of rare diseases can achieve sustained functional benefits, reduce disease-related complications, and lessen dependence on long-term replacement or supportive treatments. However, challenges in ethical considerations, regulatory requirements, manufacturing complexity, treatment costs, and limited patient access remain. Continued clinical evaluation is essential to further establish long-term safety and effectiveness. Advances in gene therapy technologies and clinical applications continue to expand therapeutic opportunities for rare diseases while supporting the broader development of precision medicine.

S. Suprianto, Y. Messe, Raehan AH. Hamzah et al. · 0 citations